


## CV of Presenter

	Name (Underline the Family Name):	Markus Andreas <u>Rüegg</u>
Job Title:	Prof. of Neurobiology	
Organization:	Biozentrum, University of Basel	
Major Field:	Neurobiology	
Education:	1985 - 1988: University of Zürich, Institute of Biochemistry. Graduate studies in Biochemistry and Neurobiology under the supervision of Dr. P. Sonderegger. Thesis Title: <i>'Purification and characterization of axonin-1, a protein secreted from axons during neurogenesis.'</i> 1979 - 1985: University of Zürich, Zürich. Study of Biochemistry. Diploma thesis at the Institute of Biochemistry under the supervision of Dr. P. Sonderegger. Title of the diploma thesis: <i>Erzeugung monoklonaler Antikörper mit Spezifität für native Zelloberflächen- Determinanten von Spinalganglien-Neuronen und deren Axone.</i>	
Job history:	August 2004: Promotion to Full Professor October 97: Promotion to Associate Professor January 97: Habilitation in Neurobiology at the Faculty of Sciences; University of Basel. 1992 - 1997: Projektleiter (equivalent to Assistant Professor) at the Biozentrum of the University of Basel 1989 - 1992: Postdoctoral fellow, Department of Neurobiology, Stanford University School of Medicine (Prof. U. J. McMahan). 1989: Postdoctoral fellow, Institute of Biochemistry.  Additional Professional Activities:  1998 - 2008: Spokesman of the "Basel Neuroscience Program" (BNP). This network for neuroscientists coordinates common activities in neurobiology in Basel (see: <a href="http://www.biozentrum.unibas.ch/neuro/">www.biozentrum.unibas.ch/neuro/</a> ). 2000 - 2004: Co-founder, member of the Management team of <b>MyoContract Ltd.</b> and acting as "Chief Research Strategist". The company focuses on the discovery, development and marketing of novel therapeutic strategies for the treatment of neuromuscular diseases and pathological forms of muscle wasting. The company is financed by private equity. Since 2005: Scientific advisor to <b>Santhera Pharmaceuticals Ltd.</b> The company was established in September 2004 as a merger from MyoContract Ltd. and Graffinity Pharmaceuticals Ltd. (Germany). With the merger, an additional 7 Mio Euros in private equity were raised resulting in total funding of more than 20 Mio Euros. This was followed by a 3 <sup>rd</sup> round of financing in 2005 and a mezzanine in September 2006. Since November 1 <sup>st</sup> 2006, the company is listed on the Swiss stock market (SWX; Swiss Exchange) and employs approximately 70 people. See <a href="http://www.santhera.com">www.santhera.com</a> for details.	